Pharma Equity Group AS (OCSE:PEG) Change In Inventory : kr0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group AS Change In Inventory?

Pharma Equity Group AS's change in inventory for the quarter that ended in Dec. 2024 was kr0.00 Mil. It means Pharma Equity Group AS's inventory stayed the same from Sep. 2024 to Dec. 2024 .

Pharma Equity Group AS's change in inventory for the fiscal year that ended in Dec. 2024 was kr0.00 Mil. It means Pharma Equity Group AS's inventory stayed the same from Dec. 2023 to Dec. 2024 .

Pharma Equity Group AS's Total Inventories for the quarter that ended in Dec. 2024 was kr0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Pharma Equity Group AS Change In Inventory Historical Data

The historical data trend for Pharma Equity Group AS's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group AS Change In Inventory Chart

Pharma Equity Group AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

Pharma Equity Group AS Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Pharma Equity Group AS Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Pharma Equity Group AS (OCSE:PEG) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Pharma Equity Group AS's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Pharma Equity Group AS's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Pharma Equity Group AS's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Pharma Equity Group AS Change In Inventory Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group AS's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Equity Group AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group AS (OCSE:PEG) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970

Website

https://www.pharmaequitygroup.com

Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .